Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Subscribe To Our Newsletter & Stay Updated
